

Multiple Technology Appraisal

Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

Dear stakeholders,

For information only

The appraisal was discussed by the technology appraisal committee on 14 December 2023. Stakeholders are reminded that access to treatments will continue while the appraisal is ongoing. This will be the case for people starting the treatments as well as those already taking the treatments. Irrespective of the appraisal outcome, the flexible commercial mechanism ensures continued access after the appraisal ends for patients already receiving any of these treatments.

On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine the most appropriate next steps. Since then, work has continued to ensure that the NICE committee outputs are clear for all parties who would be involved in any formal commercial negotiation. This initial phase is now complete.

The next phase will be commercial negotiations and NICE will prepare necessary materials for this to happen.

The ongoing post-meeting activity means that publication of final guidance will be delayed. We will update the anticipated date of final guidance publication on our website to 'TBC' as a result. This will be further updated once timelines are confirmed.

We reiterate that we are committed to giving regular updates to the community of patients, families and other interested parties while discussions continue. The content of this email is not considered confidential, and a summary will be added to the NICE website.

Kind regards,

Dr Jacoline Bouvy (*she/her*)
Programme Director – Medicines Evaluation
Centre for Health Technology Evaluation
National Institute for Health and Care Excellence
2nd Floor | 2 Redman Place | London | E20 1JQ